Nirseviml

Nirseviml is a monoclonal antibody developed for the prevention of lower respiratory tract illness caused by the respiratory syncytial virus (RSV) in infants. It is designed to provide passive immunity by binding to the RSV fusion protein. This binding prevents the virus from entering host cells and replicating. Clinical trials have demonstrated nirseviml's efficacy in reducing the incidence of medically attended RSV-associated lower respiratory tract infections. The drug is administered as a single intramuscular injection. Nirseviml is a long-acting antibody, offering protection for an extended period, typically through the RSV season. It is intended for use in newborns and infants up to a certain age, depending on the specific guidelines and recommendations from regulatory bodies. The development of nirseviml represents a significant advancement in the prevention of RSV disease, particularly for vulnerable infant populations.